Evommune (NYSE:EVMN) Insider Jeegar Pravinkumar Patel Sells 16,687 Shares of Stock

Posted by Geri Gentry on Jun 4th, 2026

Evommune, Inc. (NYSE:EVMN – Get Free Report) insider Jeegar Pravinkumar Patel sold 16,687 shares of Evommune stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $22.74, for a total transaction of $379,462.38. Following the sale, the insider directly owned 46,403 shares in the company, valued at approximately $1,055,204.22. The trade was a 26.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Evommune Trading Down 0.2%

EVMN stock opened at $19.78 on Thursday. The stock has a market cap of $712.62 million and a price-to-earnings ratio of -2.08. The firm’s 50 day moving average price is $23.98. Evommune, Inc. has a one year low of $13.89 and a one year high of $33.20.

Evommune (NYSE:EVMN – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. On average, sell-side analysts forecast that Evommune, Inc. will post -2.83 EPS for the current fiscal year.

Institutional Trading of Evommune

A number of institutional investors and hedge funds have recently bought and sold shares of EVMN. China Universal Asset Management Co. Ltd. purchased a new stake in Evommune during the fourth quarter worth about $34,000. Strs Ohio purchased a new stake in Evommune during the first quarter worth about $41,000. The Manufacturers Life Insurance Company purchased a new stake in Evommune during the fourth quarter worth about $179,000. XTX Topco Ltd purchased a new stake in Evommune during the fourth quarter worth about $321,000. Finally, Oxford Asset Management LLP purchased a new stake in Evommune during the fourth quarter worth about $335,000.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EVMN. Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Royal Bank Of Canada reissued an “outperform” rating and issued a $48.00 target price on shares of Evommune in a research report on Friday, April 10th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Evommune in a research report on Tuesday, May 26th. Stifel Nicolaus started coverage on Evommune in a research report on Friday, May 1st. They issued a “buy” rating and a $54.00 target price on the stock. Finally, Clear Str raised Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $49.25.

Read Our Latest Report on Evommune

About Evommune

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.